U.S. stock market update: ArrowHead Pharma rises over 21%, new drug news ignites market enthusiasm

U.S. Stock Market Midday Update

Arrowhead Pharma rose over 21%. Based on recent key news:

1. On July 22, Arrowhead Pharma released positive research results for its new drug Plozasiran. The drug performed excellently in the SHASTA-3 and SHASTA-4 studies and is expected to receive FDA approval by the end of 2026. This news drove the stock price up, with market expectations for annual sales of the drug reaching $10 billion. Source: Business Wire

2. On July 22, market sentiment turned bullish, with retail investors showing increased interest in Arrowhead Pharma. The stock became a hot topic, with investors expecting the stock price to quickly reach $100. Source: Stocktwits

3. On July 22, Arrowhead Pharma's stock price rose over 26% in the past five days, reflecting strong market confidence in its new drug. Source: Business Wire The biopharmaceutical industry has recently performed strongly, with significant capital inflows.

Top Stocks by Trading Volume in the Industry

Lakewood-Amedex rose 134.95%. Based on recent key news:

1. On July 22, Lakewood-Amedex released new resistance data for its Nu-3 drug. Nu-3 did not show induced resistance in continuous passage studies, supporting its membrane-disrupting mechanism and positioning it in antibiotic resistance development. This news significantly boosted the stock price.

2. On July 22, the company's statement mentioned that clinical trials may face risks, including failure to start, complete, or succeed as expected. These uncertainties could affect investor confidence but did not prevent the stock price from rising.

3. On July 22, Lakewood-Amedex's press release highlighted the development progress of its product candidates, and despite manufacturing, supply, and financing risks, the market remains optimistic about its future development. The biotechnology industry has recently performed strongly, with significant capital inflows.

Ionis Pharmaceuticals fell 3.13%, with a trading volume of $93.55 million, and there has been no significant news recently. Trading is active, with clear capital flows, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.

AbbVie rose 0.14%. Based on recent news:

1. On July 20, AbbVie relies on its two major growth drivers, Skyrizi and Rinvoq, and is expected to report strong financial performance. Additionally, the company has several exciting pipeline candidates in the rapidly growing weight loss market. These factors make AbbVie a strong buy choice for dividend investors.

2. On July 22, although AbbVie currently holds a "Moderate Buy" rating among analysts, top analysts believe there are five stocks that are more worthy of investment than AbbVie.

3. On July 22, market analysis suggests that AbbVie is a good long-term hold option. Market analysts remain optimistic about AbbVie Stocks Ranked Among the Top by Market Capitalization in the Industry

Amgen rose by 0.37%. Based on recent key news:

1. On July 21, the U.S. Tax Court may make a ruling this year that could impact Amgen's stock price. Previously, Amgen's stock price dropped by 6.5% on August 4, 2021, and by 4.3% on April 28, 2022, due to failure to timely disclose tax risks. This incident has heightened investor concern regarding the company's tax issues.

2. On July 21, Amgen's main products include Prolia for the treatment of osteoporosis and Repatha for cardiovascular events and hyperlipidemia. The strong sales performance of these products supports the rise in stock price.

3. On July 19, the biotechnology industry faces a complex ecosystem, with investors focusing on clinical trial results and financial statements, affecting market sentiment. The biotechnology industry is under policy pressure